Zevra Therapeutics, Inc. ZVRA Business Segments — Net income (loss)
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Zevra Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Zevra Therapeutics, Inc.'s business segments — net income (loss).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Zevra Therapeutics, Inc.'s business segments — net income (loss)?
- Zevra Therapeutics, Inc. (ZVRA) reported business segments — net income (loss) of $37.89M in Q1 2026.
- How has Zevra Therapeutics, Inc.'s business segments — net income (loss) changed year-over-year?
- Zevra Therapeutics, Inc.'s business segments — net income (loss) increased by 1322.7% year-over-year, from -$3.1M to $37.89M.
- What does business segments — net income (loss) mean?
- Represents the final bottom-line profitability of the business segment after all revenues, operating expenses, taxes, and non-operating items are accounted for. It is the primary measure of the segment's overall financial health and contribution to the company's total earnings.